Apolipoprotein A-IMilano and Apolipoprotein A-IParis Exhibit an Antioxidant Activity Distinct from That of Wild-Type Apolipoprotein A-I
- 16 January 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 41 (6), 2089-2096
- https://doi.org/10.1021/bi011716p
Abstract
Apolipoprotein A-IMilano (apoA-IMilano) and apoA-IParis are rare cysteine variants of apoA-I that produce a HDL deficiency in the absence of cardiovascular disease in humans. This paradox provides the basis for the hypothesis that the cysteine variants possess a beneficial activity not associated with wild-type apoA-I (apoA-IWT). In this study, a unique antioxidant activity of apoA-IMilano and apoA-IParis is described. ApoA-IMilano was twice as effective as apoA-IParis in preventing lipoxygenase-mediated oxidation of phospholipids, whereas apoA-IWT was poorly active. Antioxidant activity was observed using the monomeric form of the variants and was equally effective before and after initiation of oxidative events. ApoA-IMilano protected phospholipid from reactive oxygen species (ROS) generated via xanthine/xanthine oxidase (X/Xo) but failed to inhibit X/Xo-induced reduction of cytochrome c. These results indicate that apoA-IMilano was unable to directly quench ROS in the aqueous phase. There were no differences between lipid-free apoA-IMilano, apoA-IParis, and apoA-IWT in mediating the efflux of cholesterol from macrophages, indicating that the cysteine variants interacted normally with the ABCA1 efflux pathway. The results indicate that incorporation of a free thiol within an amphipathic α helix of apoA-I confers an antioxidant activity distinct from that of apoA-IWT. These studies are the first to relate gain of function to rare cysteine mutations in the apoA-I primary sequence.Keywords
This publication has 15 references indexed in Scilit:
- Limited proteolysis of a disulfide-linked apoA-I dimer in reconstituted HDLJournal of Lipid Research, 2001
- Apolipoprotein A-I (R151C)Paris is defective in activation of lecithin: cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux.Journal of Molecular Medicine, 1999
- At last, direct evidence that lipoxygenases play a role in atherogenesisJournal of Clinical Investigation, 1999
- Oxidation of High Density LipoproteinsPublished by Elsevier ,1998
- Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor.Journal of Clinical Investigation, 1994
- In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia.Journal of Clinical Investigation, 1993
- Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein.Journal of Clinical Investigation, 1991
- A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins.Journal of Clinical Investigation, 1980
- A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family.Journal of Clinical Investigation, 1980
- High density lipoprotein as a protective factor against coronary heart diseaseThe American Journal of Medicine, 1977